REFERENCES
1. Karsdal MA, Detlefsen S, Daniels SJ, Nielsen MJ, Krag A, Schuppan D. Is the total amount as important as localization and type of collagen in liver fibrosis attributable to steatohepatitis? Hepatology. 2020;71:346-51.
2. Villesen IF, Daniels SJ, Leeming DJ, Karsdal MA, Nielsen MJ. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis. Aliment Pharmacol Ther. 2020;52:85-97.
3. Zamani M, Alizadeh-Tabari S, Ajmera V, Singh S, Murad MH, Loomba R. Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23:1123-34.
4. Ferdek PE, Krzysztofik D, Stopa KB, et al. When healing turns into killing - the pathophysiology of pancreatic and hepatic fibrosis. J Physiol. 2022;600:2579-612.
5. Chen S, Zhou J, Wu X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int. 2021;15:611-20.
6. Cai X, Liu X, Xie W, et al. Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial. Clin Gastroenterol Hepatol. 2023;21:1893-901.e7.
7. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-90.
8. Di Zeo-Sánchez DE, Díaz-Alberola I, Pinazo-Bandera JM, et al. Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD). Br J Pharmacol. 2025;182:5303-16.
9. Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology. 2020;159:849-63.
10. Lau HC, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;22:619-38.
11. He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018;8:237-55.
12. Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell. 2019;177:428-45.e18.
13. Zhou Y, Xu H, Xu W, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther. 2013;4:34.
14. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26:1474-83.
15. Bruno S, Grange C, Collino F, et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One. 2012;7:e33115.
16. Zhang B, Wang M, Gong A, et al. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015;33:2158-68.
17. Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845-54.
18. Jin Y, Wang J, Li H, et al. Extracellular vesicles secreted by human adipose-derived stem cells (hASCs) improve survival rate of rats with acute liver failure by releasing lncRNA H19. EBioMedicine. 2018;34:231-42.
19. Zhao S, Xiu G, Wang J, et al. Engineering exosomes derived from subcutaneous fat MSCs specially promote cartilage repair as miR-199a-3p delivery vehicles in Osteoarthritis. J Nanobiotechnology. 2023;21:341.
20. Daemen S, Chan MM, Schilling JD. Comprehensive analysis of liver macrophage composition by flow cytometry and immunofluorescence in murine NASH. STAR Protoc. 2021;2:100511.
21. Wu B, Feng J, Guo J, et al. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis. Stem Cell Res Ther. 2022;13:494.
22. Li C, Deng L, Pu M, Ye X, Lu Q. Coptisine alleviates colitis through modulating gut microbiota and inhibiting TXNIP/NLRP3 inflammasome. J Ethnopharmacol. 2024;335:118680.
23. Liu Y, Luo R, Sun Z, et al. Synergistic toxicity of combined exposure to acrylamide and polystyrene nanoplastics on the gut-liver axis in mice. Biology. 2025;14:523.
24. Aimaier D, Bai W, Zhang Y, et al. Susceptibility factor TNF-α synergizes with Polygonum multiflorum to drive idiosyncratic liver injury in mice by disrupting gut microbiota composition and hepatic metabolite homeostasis. J Inflamm Res. 2025;18:9477-94.
25. Ahmadi Badi S, Tavakoli Aval H, Moradi HR, et al. Comparative study of liver injury protection by Akkermansia muciniphila and Faecalibacterium prausnitzii interventions in live and cell-free supernatant forms via targeting the hepcidin - ferroportin axis in mice with CCl4-induced liver fibrosis. Gut Pathog. 2025;17:54.
26. Oguri N, Miyoshi J, Nishinarita Y, et al.
27. Ding Y, Hou Y, Lao X. The role of Akkermansia muciniphila in disease regulation. Probiotics Antimicrob Proteins. 2025;17:2027-38.
28. Mandaliya DK, Patel S, Seshadri S. Postbiotic potential of SCFAs on metaflammation and gut microbiota alteration in diabetes. J Biosci. 2025;50:57.
32. Gan C, Wei W, Xue T, et al. Focal adhesion kinase inhibitors in fibrotic diseases therapy: development and therapeutic potential. Eur J Med Chem. 2025;296:117882.
33. Kaya E, Aksoy S, Oruc N, et al. Non-invasive tests for resmetirom treatment fail to accurately define the target population: evidence from a biopsy-proven MASLD cohort. Hepatol Forum. 2025;6:111-5.
34. Adali G, Akdogan RA. Non-invasive tests fail to ensure therapeutic precision for resmetirom in MASLD. Hepatol Forum. 2025;6:89-90.
35. Wang W, Gao Y, Chen Y, et al. TGF-β inhibitors: the future for prevention and treatment of liver fibrosis? Front Immunol. 2025;16:1583616.
36. Dumitru A, Tocia C, Bădescu AC, et al. Linking gut permeability to liver steatosis: noninvasive biomarker evaluation in MASLD patients - a prospective cross-sectional study. Medicine. 2025;104:e42476.
37. Cui C, Gao S, Shi J, Wang K. Gut-liver axis: the role of intestinal microbiota and their metabolites in the progression of metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2025;19:479-507.
38. Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health. 2021;40:50-8.
39. Mantovani A, Longo L, Thoen RU, et al. Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis. Clinics. 2024;79:100471.
40. Masihi KN, Brehmer W, Lange W, Werner H, Ribi E. Trehalose dimycolate from various mycobacterial species induces differing anti-infectious activities in combination with muramyl dipeptide. Infect Immun. 1985;50:938-40.
41. Piao C, Sang J, Kou Z, et al. Effects of exosomes derived from adipose-derived mesenchymal stem cells on pyroptosis and regeneration of injured liver. Int J Mol Sci. 2022;23:12065.
42. Choi H, Kim MY, Kim DH, et al. Quantitative biodistribution and pharmacokinetics study of GMP-grade exosomes labeled with 89Zr radioisotope in mice and rats. Pharmaceutics. 2022;14:1118.
43. Yu JX, Wu J, Chen X, et al. Gut microbiota in liver diseases: initiation, development and therapy. Front Med. 2025;12:1615839.
44. Zhang YL, Li ZJ, Gou HZ, Song XJ, Zhang L. The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis. Front Cell Infect Microbiol. 2022;12:945368.
45. Pisarello MJL, Marquez A, Chaia AP, Babot JD. Targeting gut health: probiotics as promising therapeutics in alcohol-related liver disease management. AIMS Microbiol. 2025;11:410-35.
